Background: This study set out to investigate the relationship between serum neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and various non-motor symptoms (NMSs) in patients with Parkinson's disease (PD).
Methods: The study included 37 healthy controls (HCs) and 51 PD patients. Clinical assessments of PD symptoms were conducted for all PD patients. The NMSS was utilised to evaluate the NMS burden (NMSB) in individuals. Based on the severity of NMSB, we further categorised the PD group into two subgroups: mild-moderate NMSB group and severe-very severe NMSB group. The amounts of NFL and GFAP in the serum were measured using an extremely sensitive single molecule array (Simoa) method. Statistical analyses were performed on the collected data using SPSS 26.0 and R (version 3.6.3).
Results: Serum GFAP and NFL levels in the PD group with severe-very severe NMSB were significantly higher than those in the mild-moderate NMSB group (GFAP: P < 0.007; NFL: P < 0.009). Serum NFL and GFAP levels had positive correlations with NMSS total scores (GFAP: r = 0.326, P = 0.020; NFL: r = 0.318, P = 0.023) and multiple subdomains. The relationship between the attention/memory domains of NMSS and NFL levels is significantly positive (r = 0.283, P = 0.044). Similarly, the mood/apathy domains of NMSS are also significantly positively correlated with GFAP levels (r = 0.441, P = 0.001). Patients with emotional problems or cognitive impairment had higher GFAP or NFL levels, respectively. Furthermore, it has been demonstrated that NMSs play a mediating role in the quality of life of patients with PD. Moreover, the combination of NFL and GFAP has proven to be more effective than using a single component in identifying PD patients with severe-very severe NMSB.
Conclusions: The severity of NMSs in PD patients, particularly cognitive and emotional symptoms, was found to be associated with the levels of serum NFL and GFAP. This study marks the first attempt to examine the connection between NMSs of PD and the simultaneous identification of NFL and GFAP levels.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/psyg.13088 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthesis and Large Crystal Growth of a Noncentrosymmetric Sodium Methylsulfanetriol Borate Lewis-Adduct: Na(S(OH)CH)(BO).
Inorg Chem
September 2024
Department of Chemistry, University of Houston, Houston, Texas 77204-5003, United States.
Article Synopsis
- A new compound called Na(S(OH)CH)(BO) (NMSB) has been synthesized, featuring a unique three-dimensional structure and a new methylsulfanetriol functional group.
- NMSB can form large, high-quality crystals using spontaneous crystallization and is confirmed through various analytical methods like SC-XRD and FT-IR spectroscopy.
- The compound is thermally stable up to 200 °C, highly soluble in water, and exhibits interesting optical properties, being transparent in the UV-vis region with absorption in the deep-UV range.
Relationship between increased serum neurofilament light chain and glial fibrillary acidic protein levels with non-motor symptoms in patients with Parkinson's disease.
Psychogeriatrics
March 2024
Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Background: This study set out to investigate the relationship between serum neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and various non-motor symptoms (NMSs) in patients with Parkinson's disease (PD).
Methods: The study included 37 healthy controls (HCs) and 51 PD patients. Clinical assessments of PD symptoms were conducted for all PD patients.
Gait performance and non-motor symptoms burden during dual-task condition in Parkinson's disease.
Neurol Sci
January 2023
China National Clinical Research Center for Neurological Diseases (NCRC-ND), Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 119 South 4th Ring West Road, Fengtai District, Beijing, 100070, China.
Introduction: Impaired gait is observed in patients with Parkinson's disease (PD) in both single-task (ST) and dual-task (DT) conditions. Non-motor symptoms (NMSs), another vital symptom future experienced along the PD disease trajectory, contribute to gait performance in PD. However, whether DT gait performance is indicative of NMS burden (NMSB) remains unknown.
View Article and Find Full Text PDFThe diagnostic and surgical challenges of small bowel disease not involving the duodenum.
Ann Ital Chir
September 2021
Background: Because of the lack of specific signs and symptoms, benign and malignant small bowel disease (SB) diagnoses and their treatments are very difficult. The aim of this study was to determine the challenges of diagnostic and surgical treatment of SB diseases.
Material And Methods: Of 51 patients, 29 (56.
Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson's disease.
Brain Behav
May 2021
Department of Neurosciences, King's College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK.
Background: Identifying predictors of incident cognitive impairment (CI), one of the most problematic long-term outcomes, in Parkinson's disease (PD) is highly relevant for personalized medicine and prognostic counseling. The Nonmotor Symptoms Scale (NMSS) provides a global clinical assessment of a range of NMS, reflecting NMS burden (NMSB), and thus may assist in the identification of an "at-risk" CI group based on overall NMSB cutoff scores.
Methods: To investigate whether specific patterns of PD NMS profiles predict incident CI, we performed a retrospective longitudinal study on a convenience sample of 541 nondemented PD patients taking part in the Nonmotor Longitudinal International Study (NILS) cohort, with Mini-Mental State Examination (MMSE), NMSS, and Scales for Outcomes in PD Motor Scale (SCOPA Motor) scores at baseline and last follow-up (mean 3.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!